Skip to main content

Table 5 Univariate analysis for estimating factors associated with a 3-month response after intravitreal injection of ranibizumab

From: Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration

Variables P value* OR (95 % CI)
Sex (male) 0.521 1.635 (0.365–7.326)
Age (years) 0.945 1.004 (0.894–1.128)
Eye (OD) 0.237 0.400 (0.088–1.826)
Lens status (phakic eye) 1.000 N/A
Baseline subfoveal CT (μm) 0.296 0.994 (0.984–1.005)
Baseline mean peripapillary CT (μm) 0.789 0.998 (0.981–1.015)
Decreased amount of subfoveal CT (μm) 0.097 1.030 (0.995–1.066)
Decreased proportion of subfoveal CT (%) 0.007 1.124 (1.033–1.223)
Decreased amount of mean peripapillary CT (μm) 0.094 1.041 (0.993–1.092)
Decreased proportion of mean peripapillary CT (%) 0.077 1.055 (0.994–1.120)
Decreased amount of mean temporal peripapillary CT (μm) 0.061 1.043 (0.998–1.090)
Decreased proportion of mean temporal peripapillary CT (%) 0.029 1.070 (1.007–1.137)
  1. *P value based on logistic regression analysis
  2. OD oculus dexter, CT choroidal thickness, N/A not applicable